Left ventricular end-diastolic pressure-guided hydration for the prevention of contrast-induced acute kidney injury in patients with stable ischemic heart disease: the LAKESIDE trial

Marashizadeh, Armin; Sanati, Hamid Reza; Sadeghipour, Parham; Peighambari, Mohamad Mehdi; Moosavi, Jamal; Shafe, Omid; Firouzi, Ata; Zahedmehr, Ali; Maadani, Mohsen; Shakerian, Farshad; Kiani, Reza; Mohebbi, Bahram; Alemzadeh‐Ansari, Mohammad Javad; Tahvili, Reza; Naghavi, Batoul

doi:10.1007/s11255-019-02235-w

Cited by 17 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent years, vascular administration of iodinated contrast media (CM) has been widely used in patients undergoing diagnostic cardiac angiography and percutaneous coronary intervention [1]. Contrast-induced acute kidney injury (CI-AKI) occurs in more than 5-15% of patients after percutaneous coronary intervention via CM [2], which is associated with risk factors, such as advanced age, diabetes, and hypertension [3].…”

Section: Introductionmentioning

confidence: 99%

Acetylbritannilactone attenuates contrast-induced acute kidney injury through its anti-pyroptosis effects

Chen

Yang

et al. 2020

Bioscience Reports

View full text Add to dashboard Cite

Contrast-induced acute kidney injury (CI-AKI) is a severe complication caused by intravascular applied radial contrast media (CM). Pyroptosis is a lytic type of cell death inherently associated with inflammation response and the secretion of pro-inflammatory cytokines following caspase-1 activation. The aim of the present study was to investigate the protective effects of acetylbritannilactone (ABL) on iopromide (IOP)-induced acute renal failure and reveal the underlying mechanism. In vivo and in vitro, IOP treatment caused renal damage and elevated the caspase-1 (+) propidium iodide (PI) (+) cell count, interleukin (IL)-1β and IL-18 levels, lactate dehydrogenase (LDH) release, and the relative expression of nucleotide-binding domain, leucine-rich repeat containing protein 3 (NLRP3), apoptosis-associated speck-like protein (ASC), and gasdermin D (GSDMD), suggesting that IOP induces AKI via the activation of pyroptosis. Furthermore, the pretreatment of ABL partly mitigated the CI-AKI, development of pyroptosis, and subsequent kidney inflammation. These data revealed that ABL partially prevents renal dysfunction and reduces pyroptosis in CI-AKI, which may provide a therapeutic target for the treatment of CM-induced AKI.

show abstract

Section: Introductionmentioning

confidence: 99%

Acetylbritannilactone attenuates contrast-induced acute kidney injury through its anti-pyroptosis effects

Chen

Yang

et al. 2020

Bioscience Reports

View full text Add to dashboard Cite

show abstract

“…In our cohort, the incidence of CA-AKI was 9.7–12 % between 2013 and 2017, which was similar to the previous study regarding patients undergoing selected or emergent procedures. The incidence of CA-AKI has been reported to approximately range from 7.0 to 22.7 % [ 14 – 16 ]. Direct and indirect effects, as well as hemodynamic perturbations, were considered to be the main mechanisms of kidney injury caused by contrast agents.…”

Section: Discussionmentioning

confidence: 99%

Trends in incidence and long-term prognosis of acute kidney injury following coronary angiography in Chinese cohort with 11,943 patients from 2013 to 2017: an observational study

Liu

Lai

et al. 2021

BMC Nephrol

View full text Add to dashboard Cite

Background Contrast-associated acute kidney injury (CA-AKI) is a common complication with poor prognosis after coronary angiography (CAG). With the prevention methods widely being implemented, the temporal trends of incidence and mortality of CA-AKI are still unknown over the last five years. The study aims to determine the incidence and prognosis of CA-AKI in China. Methods This retrospective cohort study was based on the registry at Guangdong Provincial People’s Hospital in China (ClinicalTrials.gov NCT04407936). We analyzed data from hospitalization patients who underwent CAG and with preoperative and postoperative serum creatinine (Scr) values from January 2013 to December 2017. Results 11,943 patients were included in the study, in which the mean age was 63.01 ± 10.79 years and 8,469 (71.1 %) were male. The overall incidence of CA-AKI was 11.2 %. Compared with 2013, the incidence of CA-AKI in 2017 was significantly increased from 9.7 to 13.0 % (adjusted odds ratios [aOR], 1.38; 95 %CI, 1.13–1.68; P-value < 0.01, P for trend < 0.01). The temporal trends of incidence among patients of different ages and genders yielded similar findings. During a standardized follow-up of 1 year, 178 (13.7 %) CA-AKI patients died in total, which showed no obvious decreased trend in this 5 five years from 21.1 to 16.5 (adjusted hazard ratio [aHR], 0.72; 95 %CI, 0.36–1.45; P-value = 0.35, P for trend = 0.24). Conclusions Our Chinese cohort showed that the incidence of CA-AKI increased significantly, while CA-AKI associated mortality showed no obvious decreased trend in the last five years. Our findings support more active measures to prevent CA-AKI and improve the prognosis of CA-AKI patients.

show abstract

“…Частота развития КИ-ОПП не различалась значимо у группы исследования и группы сравнения; также не было зафиксировано разницы в частоте отдаленных осложнений. Таким образом, метод определения объема гидратации путем измерения конечнодиастолического давления в левом желудочке не дает преимуществ при планировании вмешательств [67].…”

Section: ки-опп: современная точка зренияunclassified

Contrast-induced acute renal injury: the modern state of issue

Sinitsyn

Filatova

Мершина

2022

Medicinskaâ vizualizaciâ

View full text Add to dashboard Cite

The concept of “contrast-induced acute renal injury” (CI-AKI) is an increase in the level of plasma creatinine, recorded within 48 hours after contrast drug administration. This condition is the third most common cause of chronic renal failure occurring in a hospital. Despite the rather frequent occurrence of this phenomenon, it is not completely clear whether all such cases can really be explained by the exceptionally wide spread of procedures with contrast agent administration, because a decrease in kidney function is often found in inpatient patients. Since there is no treatment for CI-AKI, many groups of scientists have attempted to develop a prevention regimen. However, such measures are fraught with a number of difficulties: possible consequences for patients, logistical difficulties in a medical institution, costs of funds. The effectiveness of these measures has also not been unequivocally proven. In particular, in the course of a large AMACING study, it was shown that hydration does not reduce the likelihood of developing CI-AKI, but significantly increases the patient's treatment costs and can cause specific complications. In addition, there is a lot of literature evidence in favor of the fact that the hydration technique is effective for preventing a decrease in kidney function only in patients who have undergone intra-arterial administration of a contrast agent. Thus, the need for drug prevention of CI-AKI is currently being questioned, research in this area is actively continuing.

show abstract

Left ventricular end-diastolic pressure-guided hydration for the prevention of contrast-induced acute kidney injury in patients with stable ischemic heart disease: the LAKESIDE trial

Cited by 17 publications

References 38 publications

Acetylbritannilactone attenuates contrast-induced acute kidney injury through its anti-pyroptosis effects

Acetylbritannilactone attenuates contrast-induced acute kidney injury through its anti-pyroptosis effects

Trends in incidence and long-term prognosis of acute kidney injury following coronary angiography in Chinese cohort with 11,943 patients from 2013 to 2017: an observational study

Contrast-induced acute renal injury: the modern state of issue

Contact Info

Product

Resources

About